Literature DB >> 31005464

Progressive reduction of auditory evoked gamma in first episode schizophrenia but not clinical high risk individuals.

Naoya Oribe1, Yoji Hirano2, Elisabetta Del Re3, Larry J Seidman4, Raquelle I Mesholam-Gately4, Kristen A Woodberry4, Joanne D Wojcik4, Takefumi Ueno5, Shigenobu Kanba6, Toshiaki Onitsuka6, Martha E Shenton7, Jill M Goldstein8, Margaret A Niznikiewicz3, Robert W McCarley3, Kevin M Spencer9.   

Abstract

The early auditory-evoked gamma band response (EAGBR) may serve as an index of the integrity of fast recurrent inhibition or synaptic connectivity in the auditory cortex, where abnormalities in individuals with schizophrenia have been consistently found. The EAGBR has been rarely investigated in first episode schizophrenia patients (FESZ) and individuals at clinical high risk (CHR) for schizophrenia, and never been compared directly between these populations nor evaluated longitudinally. Here we examined the EAGBR in FESZ, CHR, and matched healthy controls (HC) at baseline and 1-year follow-up assessments to determine whether the EAGBR was affected in these clinical groups, and whether any EAGBR abnormalities changed over time. The electroencephalogram was recorded with a dense electrode array while subjects (18 FESZ, 18 CHR, and 40 HC) performed an auditory oddball task. Event-related spectral measures (phase locking factor [PLF] and evoked power) were computed on Morlet-wavelet-transformed single epochs from the standard trials. At baseline, EAGBR PLF and evoked power did not differ between groups. FESZ showed progressive reductions of PLF and evoked power from baseline to follow-up, and deficits in PLF at follow-up compared to HC. EAGBR peak frequency also increased at temporal sites in FESZ from baseline to follow-up. Longitudinal effects on the EAGBR were not found in CHR or HC, nor did these groups differ at follow-up. In conclusion, we detected neurophysiological changes of auditory cortex function in FESZ during a one-year period, which were not observed in CHR. These findings are discussed within the context of neurodevelopmental models of schizophrenia. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical high risk; EEG; First episode schizophrenia; Gamma oscillation

Mesh:

Year:  2019        PMID: 31005464     DOI: 10.1016/j.schres.2019.03.025

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Test-retest reliability of tone- and 40 Hz train-evoked gamma oscillations in female rats and their sensitivity to low-dose NMDA channel blockade.

Authors:  Muhammad Ummear Raza; Digavalli V Sivarao
Journal:  Psychopharmacology (Berl)       Date:  2021-05-04       Impact factor: 4.530

Review 2.  Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

Authors:  Diana O Perkins; Clark D Jeffries; Kim Q Do
Journal:  Biol Psychiatry       Date:  2020-04-02       Impact factor: 13.382

3.  Neurophysiological Face Processing Deficits in Patients With Chronic Schizophrenia: An MEG Study.

Authors:  Naotoshi Ohara; Yoji Hirano; Naoya Oribe; Shunsuke Tamura; Itta Nakamura; Shogo Hirano; Rikako Tsuchimoto; Takefumi Ueno; Osamu Togao; Akio Hiwatashi; Tomohiro Nakao; Toshiaki Onitsuka
Journal:  Front Psychiatry       Date:  2020-09-03       Impact factor: 4.157

4.  Long-Term Test-Retest Reliability of Auditory Gamma Oscillations Between Different Clinical EEG Systems.

Authors:  Yoji Hirano; Itta Nakamura; Shunsuke Tamura; Toshiaki Onitsuka
Journal:  Front Psychiatry       Date:  2020-09-02       Impact factor: 4.157

5.  Editorial: Current MEG Research in Psychiatry.

Authors:  Yoji Hirano; Peter J Uhlhaas
Journal:  Front Psychiatry       Date:  2021-02-02       Impact factor: 4.157

Review 6.  Trends in big data analyses by multicenter collaborative translational research in psychiatry.

Authors:  Toshiaki Onitsuka; Yoji Hirano; Kiyotaka Nemoto; Naoki Hashimoto; Itaru Kushima; Daisuke Koshiyama; Michihiko Koeda; Tsutomu Takahashi; Yoshihiro Noda; Junya Matsumoto; Kenichiro Miura; Takanobu Nakazawa; Takatoshi Hikida; Kiyoto Kasai; Norio Ozaki; Ryota Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2022-01       Impact factor: 12.145

Review 7.  A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology.

Authors:  Daniel C Javitt; Steven J Siegel; Kevin M Spencer; Daniel H Mathalon; L Elliot Hong; Antigona Martinez; Cindy L Ehlers; Atheir I Abbas; Tobias Teichert; Peter Lakatos; Thilo Womelsdorf
Journal:  Neuropsychopharmacology       Date:  2020-05-06       Impact factor: 8.294

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.